5 December 2024
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is delighted to announce it has been awarded a new
contract with a long-standing, globally recognised pharmaceutical
client. The project, valued at £157k, will leverage Physiomics'
expertise in Pharmacokinetic-Pharmacodynamic ("PKPD") modelling to
inform critical pre-clinical and clinical dosing and scheduling
decisions for a novel cancer treatment combination. Delivery of the
project is expected to complete within the next 12
months.
This new project represents a significant
expansion of the ongoing collaboration between Physiomics and its
client, marking the first incorporation of an Antibody-Drug
Conjugate ("ADC") into the company's Virtual Tumour ("VT")
modelling platform. ADCs are a rapidly advancing class of targeted
therapies in oncology, offering enhanced precision by enabling
tumour specific delivery of potent cytotoxic payloads. This project
positions Physiomics at the forefront of this exciting field of
drug development.
Dr Peter
Sargent, CEO of Physiomics,
commented:
"This new
contract demonstrates the strength and longevity of our
collaboration with one of the world's leading pharmaceutical
companies and reflects their trust in our modelling expertise to
support the development of advanced therapies. We are particularly
excited to expand our Virtual Tumour platform to include ADCs - a
hot topic in cancer treatment right now. We look forward to
starting work on this project and continue to demonstrate our
expertise across a diverse range of therapeutic
approaches."
Enquiries:
Physiomics
plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc combines cutting edge
PKPD and QSP modelling and data science techniques, along with deep
biology expertise, to help biotech and pharma companies streamline
their drug development journeys.
Our approach is to derive insight
from all relevant data in order to de-risk decision making and
optimise design research across discovery, pre-clinical and
clinical studies.
Through use of bespoke models and
our proprietary Virtual Tumour technology, the Physiomics team has
informed the development of over 100 commercial projects, over 50
targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle
Therapeutics, Numab Therapeutics & CRUK.
